Close

CPIC® Guideline for NSAIDs based on CYP2C9 genotype

Most recent guideline publication:

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020)

Updates since publication:

No updates on dosing recommendations since publication.

Tables provided in the main manuscript of the guideline:

Table 1. Assignment of likely CYP2C9 phenotypes based on genotypes
Table 2. Therapeutic recommendations for celecoxib, flurbiprofen, lornoxicam and ibuprofen based on CYP2C9 phenotype
Table 3. Therapeutic recommendations for meloxicam based on CYP2C9 phenotype
Table 4. Therapeutic recommendations for piroxicam and tenoxicam based on CYP2C9 phenotype

Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020)

Tables and figures provided in the guideline publication supplement or referenced in the guidelinea:

Supplemental Table S1. Evidence linking CYP2C9 genotype to celecoxib phenotype
Supplemental Table S2. Evidence linking CYP2C9 genotype to flurbiprofen phenotype
Supplemental Table S3. Evidence linking CYP2C9 genotype to lornoxicam phenotype
Supplemental Table S4. Evidence linking CYP2C9 genotype to ibuprofen phenotype
Supplemental Table S5. Evidence linking CYP2C9 genotype to meloxicam phenotype
Supplemental Table S6. Evidence linking CYP2C9 genotype to piroxicam phenotype
Supplemental Table S7. Evidence linking CYP2C9 genotype to tenoxicam phenotype
Supplemental Table S8. Evidence linking CYP2C9 genotype to NSAID phenotype
Supplemental Table S9. Evidence linking CYP2C9 genotype to aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen phenotype (No recommendation provided in guideline)
Supplemental Table S10. Evidence linking CYP2C8 genotype to ibuprofen and diclofenac phenotype (No recommendation provided in guideline)
Supplemental Table S11. Linkage disequilibrium between CYP2C9*2 and CYP2C8*3 across populations
Supplemental Table S12. Clinical pharmacokinetics of selected NSAIDs
Figure S2. Meta-analysis of the effect of CYP2C9 genotypes on celecoxib exposure
Figure S3. Meta-analysis of the effect of CYP2C9 genotypes on ibuprofen exposure
Figure S4. Meta-analysis of the effect of CYP2C9 genotypes on meloxicam exposure
CYP2C9 allele definition table
CYP2C9 allele functionality table
CYP2C9 frequency table
CYP2C9 diplotype-phenotype table

Gene resource mapping

CYP2C9 gene resource mappings

Drug resource mapping

Celecoxib

Flurbiprofen

Lornoxicam

Ibuprofen

Meloxicam

Piroxicam

Tenoxicam

Clinical decision support:b

Celecoxib pre- and post-test alerts and flow chart

Flurbiprofen pre- and post-test alerts and flow chart

Lornoxicam pre- and post-test alerts and flow chart

Ibuprofen pre- and post-test alerts and flow chart

Meloxicam pre- and post-test alerts and flow chart

Piroxicam pre- and post-test alerts and flow chart

Tenoxicam pre- and post-test alerts and flow chart

aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.

bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.